4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™

All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kg Cardiac biopsy demonstrated selective and widespread transgene expression within ~50% of cardiomyocytes Engaging with FDA to lift clinical hold and resume enrollment with updated exclusion criteria and highly effective rituximab/sirolimus immunosuppressive regimen to reduce risk of atypical hemolytic uremic syndrome (“aHUS”) Otherwise, generally well-tolerated with no liver, heart, or dorsal root ganglia (“DRG”) toxicity observed Company to host live webcast today at 4:30 p.m. EST EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced updated interim safety and efficacy data from the two 4D-310 INGLAXA Phase 1/2 clinical trials for Fabry disease cardiomyopathy. All three patients with 12 months of follow-up demonstrated improvement on cardiac contractility, exercise capacity and quality of life endpoints. Treatment was generally well tolerated, with transient acute aHUS being the only significant adverse event. Following a detailed investigation into the etiology of aHUS, 4DMT is engaging with the FDA to resume enrollment based on updated exclusion criteria and the highly effective rituximab/sirolimus immunosuppressive regimen. Data will also be presented at the WORLD Symposium ™ 2023 in Orlando, Florida on February 25th, 2023. “As demonstrated by the positive cardiac outcomes and biopsy biomarker data, these clinical proof-of-concept results with 4D-310 mark another important milestone for 4DMT,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “This is our third proprietary vector that has been validated in clinical trials across three different therapeutic areas, which further validates our Therapeutic Vector Evolution platform. We are developing 4D-310 for the treatment of Fabry disease cardiomyopathy, which is the primary cause of death and not addressed by current therapies. In addition, our focus on patient safety led us to voluntarily pause enrollment on our two INGLAXA trials in January 2023 after observing an aHUS dose-limiting toxicity, and FDA subsequently put the program on clinical hold. Following an in-depth investigation in collaboration with world experts in immunology and AAV gene therapy to understand and mitigate aHUS, we are confident that the rituximab and sirolimus immunosuppressive regimen and updated exclusion criteria will mitigate safety risks and potentially further improve patient benefit.” INGLAXA Phase 1/2 Clinical Trials Design Dose-escalation and dose-expansion trial assessing a single intravenous infusion of 4D-310 in a broad and diverse Fabry disease patient population Treated patients in three geographies: INGLAXA-1 (U.S.) and INGLAXA-2 (Taiwan and Australia) Enrolled six patients, each treated with 1E13 vg/kg of 4D-310 and a prophylactic corticosteroid immunosuppressive regimen Assessed FDA-recommended pivotal trial cardiac endpoints in three patients who completed 12 months of follow-up (cut-off date of December 5, 2022) including: Left ventricular contractility – Change from baseline at 12 months in global longitudinal strain on echocardiography (GLS on ECHO) Exercise capacity – Change from baseline at 12 months in cardiopulmonary exercise testing (peak VO 2 by CPET) Quality of life status – Change from baseline at 12 months in Kansas City Cardiomyopathy Questionnaire (KCCQ) Cardiac biopsy available from one patient in the INGLAXA-2 trial Cardiac Outcomes Cardiac contractility (GLS) assessed on ECHO :  meaningful improvement in 3 of 3 patients (GLS worsened on ERT natural history study) Exercise capacity (peak VO 2 ) assessed by CPET :  meaningful improvement in 2 of 3 patients (worsened on ERT natural history study) Cardiac quality of life (physical limitations, symptoms) assessed with KCCQ :  clinically meaningful improvement in 2 of 2 patients, and the third remained stable at 100% (no possibility for improvement from baseline) Cardiac biopsy :  healthy tissue, no inflammation, and widespread transgene expression in ~50% of cardiomyocytes; transgene expression was highly selective for cardiomyocytes: ~4.4 genomes/cardiomyocyte (qPCR) and ~16.2 RNA transcripts/cardiomyocyte (RT-qPCR) 4D-310 Cardiac clinical endpoints results summary (data cut-off date of December 5, 2022): Pts (U.S. Trial) GLS (Echo) Peak VO 2 (CPET) (mL/kg/min) Cardiac QoL (KCCQ) Baseline Week 52 Baseline Week 52 Baseline Week 52 (Overall Summary Score) Week 52 (Clinical Summary Score) 1 Borderline Improved (-2.5%) Abnormal Improved (+2.0) Normal Stable 100% Stable 100% 2 Normal Improved (-1.1%) Abnormal Improved (+7.0) Abnormal Improved (+11.7) Improved (+5.7) 3 Borderline Improved (-3.3%) Abnormal -2.2 Abnormal Improved (+7.3) Improved (+10.4) ERT natural history   Worsened (+1.1%) 1   Worsened (-1.8) 2   n.a. n.a. 1. Minimal detectable difference (MDD): GLS (1.5%); Borderline: GLS range of -16 to -18% 2. Minimal clinically important difference (MCID): peak VO2 (1.5 mL/kg/min); KCCQ (summary scores 5 points) References: 1. Nordin et al. Circ Cardiovasc Imaging 2019:e009430; 2. Lobo, Intern Med J 2008;38:407 Safety and Tolerability Treatment was generally well-tolerated except as noted below – no liver, heart, or DRG toxicity observed Transient acute aHUS (n=3): ~Day 3-7 onset; resolution started within ~1-4 days Known class effect of IV administered AAV due to rapid anti-AAV capsid IgM antibody rise, capsid binding and complement pathway activation Investigation of single grade 4 DLT aHUS patient indicated that complement pathway activation, which drives aHUS, was present before 4D-310 dosing. Investigation of IV administered AAV associated aHUS and development of mitigation strategies were conducted in close collaboration with world experts in immunology and gene therapy including Paul J. Utz, M.D., Professor of Medicine, Immunology and Rheumatology Stanford University; Dimitris Mastellos, PhD, National Center for Research, Greece; and Barry Byrne, MD, PhD, University of Florida. Next Steps for Development of 4D-310 Align with FDA on plan to remove clinical hold and resume enrollment following protocol amendment including the following: Implement highly effective rituximab/sirolimus immunosuppressive regimen Exclude patients with pre-dosing complement activation Continue current protocol follow-up for all six patients enrolled to date, including cardiac efficacy assessments supportive of regulatory approval: peak VO 2 (CPET), quality of life (KCCQ), and left ventricular function (GLS on ECHO) Phase 3 CMC plans, assays & trial design aligned with FDA Provide program update in the second half of 2023 Webcast Information: 4D Molecular Therapeutics will host a conference call today, Wednesday February 22, 2023 at 4:30 p.m. EST. to discuss clinical data and development plans. Dr. Paul J. Utz will join today's webcast to discuss immunology related to intravenous AAV therapy. Title: 4D-310 INGLAXA Phase 1/2 Clinical Data Webcast and Q&A Date/Time: Wednesday, February 22, 2023, 4:30 p.m. EST Registration: Link     An archived copy of the webcast will be available for up to one year by visiting the “Investors & Media” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events . About 4D-310 and Fabry Disease Cardiomyopathy 4D-310 utilizes the targeted and customized C102 vector to efficiently deliver a functional copy of the GLA gene and was designed for a unique mechanism of action, specifically to directly correct the AGA enzyme function within cardiomyocytes (heart muscle cells) after a single low dose IV administration. C102 was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform; we created this platform utilizing principles of directed evolution, a Nobel Prize-winning technology. The product is designed to generate both high local production of AGA directly within critically affected organs, including heart, blood vessels and kidney, as well as the potential for systemic tissue cross-correction. This product design has the potential to treat and potentially reverse the cardiomyopathy in Fabry patients which is the leading cause of death, as well as other significant unmet medical needs in patients with Fabry disease. Affecting more than 50,000 people in the United States and European Union, Fabry disease is a genetic disorder of the GLA gene that results in the body’s inability to produce an enzyme called alpha-galactosidase or AGA, causing accumulation of the substrate globotriaosylceramide (Gb3) in critical organs, including the heart, kidney, and blood vessels. Such substrate accumulation can lead to life-threatening hypertrophic cardiomyopathy, heart failure, arrhythmias, various degrees of kidney dysfunction and cerebrovascular stroke. Fabry disease progression results in increased morbidity, mortality and cost of care. Significant unmet medical needs remain for these patients despite enzyme replacement therapy (ERT), the current standard of care. ERT requires biweekly intravenous dosing which markedly decreases patients’ quality of life. In addition, while benefit has been demonstrated in the kidney, ERT has not been shown to clearly benefit the heart. Cardiovascular disease remains the leading cause of death and disability in Fabry disease patients. About 4DMT 4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. 4DMT seeks to unlock the full potential of genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution, which combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent targeted and evolved vectors for use in our product candidates. All of our vectors are proprietary to 4DMT and were invented at 4DMT, including the vectors utilized in our clinical-stage and preclinical pipeline product candidates: R100, A101, and C102. The Company is initially focused on five clinical-stage product candidates in three therapeutic areas for both rare and large market diseases: ophthalmology, pulmonology, and cardiology (Fabry disease cardiomyopathy). The 4DMT targeted and evolved vectors were invented with the goal of being delivered at relatively low doses through clinically routine, well-tolerated, and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently advancing five product candidates in clinical development: 4D-150 for wet AMD and DME, 4D-710 for cystic fibrosis lung disease, 4D-310 for Fabry disease cardiomyopathy, 4D-125 for XLRP, and 4D-110 for choroideremia. The 4D preclinical product candidates in development are: 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin deficiency. 4D-150, 4D-710, 4D-310, 4D-125, and 4D-110 are our product candidates in clinical development and have not yet been approved for marketing by the US FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of 4D-150, 4D-710, 4D-310, 4D-125, or 4D-110 for the therapeutic uses for which they are being studied. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, and clinical benefits, as well as the plans and related timing for the clinical development of 4D-310, including the implications of interim clinical data from 4D-310’s Phase 1/2 clinical trial. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward looking statements. Contacts: Media: Katherine Smith Evoke Canale [email protected] Investors: August J. Moretti Chief Financial Officer [email protected] Irina Koffler LifeSci Advisors [email protected] 917-734-7387 #top .av-special-heading.av-lfbghqew-6a8250e9e7368dec7e0d9a3b737a7593 { padding-bottom: 10px; } body .av-special-heading.av-lfbghqew-6a8250e9e7368dec7e0d9a3b737a7593 .av-special-heading-tag .heading-char { font-size: 25px; } .av-special-heading.av-lfbghqew-6a8250e9e7368dec7e0d9a3b737a7593 .av-subheading { font-size: 15px; } About 4DMT Our 4DMT genetic medicine engine holds the potential to generate transformative therapies that have the power to improve patient lives, or even cure disease. #top .av-special-heading.av-lfbgitgh-b6f7f67edb1be3c2b890ac351a5dce41 { padding-bottom: 10px; } body .av-special-heading.av-lfbgitgh-b6f7f67edb1be3c2b890ac351a5dce41 .av-special-heading-tag .heading-char { font-size: 25px; } .av-special-heading.av-lfbgitgh-b6f7f67edb1be3c2b890ac351a5dce41 .av-subheading { font-size: 15px; } Navigation Home About Our Approach Core Values Leadership Leadership in the News Board of Directors Advisors Retina Advisory Board Scientific Advisory Board Technology Platform Product Engine Pipeline Pipeline Clinical Candidates Scientific Presentations Our Purpose Retinal Diseases Pulmonary Diseases Investors Careers Join Our Team Living Our Core Values 4Diversity What We Offer Open Positions Contact #top .av-special-heading.av-lfbgj2zz-0d32d30aa8f7c68168e79b9f2740b416 { padding-bottom: 10px; } body .av-special-heading.av-lfbgj2zz-0d32d30aa8f7c68168e79b9f2740b416 .av-special-heading-tag .heading-char { font-size: 25px; } .av-special-heading.av-lfbgj2zz-0d32d30aa8f7c68168e79b9f2740b416 .av-subheading { font-size: 15px; } Location 5858 Horton St. Suite 455 Emeryville, CA 94608 (510) 505-2680 [email protected] © 2026 4D Molecular Therapeutics. All rights reserved. Contact Privacy Notice Site Terms LinkedIn Scroll to top This site uses cookies to improve our website and provide personalized services to you - both on this website and through other media. To find out more about the cookies we use, see our Privacy Notice. If you decline, your information won't be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked. Accept all Cookies Reject all Cookies Cookies Settings #top .av-special-heading.av-av_heading-e9726c5b3ba47c61a37656c1e7d02a7a { margin: 10px 0 0 0; padding-bottom: 10px; } body .av-special-heading.av-av_heading-e9726c5b3ba47c61a37656c1e7d02a7a .av-special-heading-tag .heading-char { font-size: 25px; } .av-special-heading.av-av_heading-e9726c5b3ba47c61a37656c1e7d02a7a .av-subheading { font-size: 15px; } Cookie and Privacy Settings #top .hr.av-jhe1dyat-381e073337cc8512c616f9ce78cc22d9 { margin-top: 0px; margin-bottom: 0px; } .hr.av-jhe1dyat-381e073337cc8512c616f9ce78cc22d9 .hr-inner { width: 100%; } How we use cookies We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website. Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer. Essential Website Cookies These cookies are strictly necessary to provide you with services available through our website and to use some of its features. Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site. We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain. We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings. Check to enable permanent hiding of message bar and refuse all cookies if you do not opt in. We need 2 cookies to store this setting. Otherwise you will be prompted again when opening a new browser window or new a tab. Click to enable/disable essential site cookies. Other external services We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page. Google Webfont Settings: Click to enable/disable Google Webfonts. Google Map Settings: Click to enable/disable Google Maps. Google reCaptcha Settings: Click to enable/disable Google reCaptcha. Vimeo and Youtube video embeds: Click to enable/disable video embeds. Privacy Policy You can read about our cookies and privacy settings in detail on our Privacy Policy Page. Accept settings Hide notification only /* <![CDATA[ */ var avia_framework_globals = avia_framework_globals || {}; avia_framework_globals.frameworkUrl = 'https://4dmoleculartherapeutics.com/wp-content/themes/enfold/framework/'; avia_framework_globals.installedAt = 'https://4dmoleculartherapeutics.com/wp-content/themes/enfold/'; avia_framework_globals.ajaxurl = 'https://4dmoleculartherapeutics.com/wp-admin/admin-ajax.php'; /* ]]> */ var SFM_template = '<div class="sfm-rollback sfm-color1 sfm-theme-none sfm-label-visible sfm-label-none " style="">\r\n <div role=\'button\' tabindex=\'0\' aria-haspopup="true" class=\'sfm-navicon-button x sf_label_default \'><div class="sfm-navicon"></div> </div>\r\n</div>\r\n<div id="sfm-sidebar" style="opacity:0" data-wp-menu-id="2" class="sfm-theme-none sfm-hl-text sfm-indicators">\r\n <div class="sfm-scroll-wrapper sfm-scroll-main">\r\n <div class="sfm-scroll">\r\n <div class="sfm-sidebar-close"></div>\r\n <div class="sfm-logo sfm-no-image">\r\n <div class="sfm-title"></div>\r\n </div>\r\n <nav class="sfm-nav">\r\n <div class="sfm-va-middle">\r\n <ul id="sfm-nav" class="menu"><li id="menu-item-658" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-658"><a href="https://4dmoleculartherapeutics.com/">Home</a></li>\n<li id="menu-item-660" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-660"><a href="https://4dmoleculartherapeutics.com/about/">About</a>\n<ul class="sub-menu">\n\t<li id="menu-item-710" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-710"><a href="https://4dmoleculartherapeutics.com/about/#our-approach">Our Approach</a></li>\n\t<li id="menu-item-711" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-711"><a href="https://4dmoleculartherapeutics.com/about/#core-values">Core Values</a></li>\n\t<li id="menu-item-712" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-712"><a href="https://4dmoleculartherapeutics.com/about/#leadership">Leadership</a></li>\n\t<li id="menu-item-712" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-712"><a href="https://4dmoleculartherapeutics.com/about/#leadership-in-the-news">Leadership in the News</a></li>\n\t<li id="menu-item-713" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-713"><a href="https://4dmoleculartherapeutics.com/about/#board-of-directors">Board of Directors</a></li>\n\t<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-713"><a href="https://4dmoleculartherapeutics.com/about/#advisors">Advisors</a></li>\n\t<li id="menu-item-713" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-713"><a href="https://4dmoleculartherapeutics.com/about/#oab">Retina Advisory Board</a></li>\n\t<li id="menu-item-713" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-713"><a href="https://4dmoleculartherapeutics.com/about/#sab">Scientific Advisory Board</a></li>\n</ul>\n</li>\n<li id="menu-item-1024" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1024"><a href="https://4dmoleculartherapeutics.com/technology/">Technology</a>\n<ul class="sub-menu">\n\t<li id="menu-item-714" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-714"><a href="https://4dmoleculartherapeutics.com/technology/#platform">Platform</a></li>\n\t<li id="menu-item-715" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-715"><a href="https://4dmoleculartherapeutics.com/technology/#product-engine">Product Engine</a></li>\n</ul>\n</li>\n<li id="menu-item-662" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-662"><a href="https://4dmoleculartherapeutics.com/pipeline/">Pipeline</a>\n<ul class="sub-menu">\n\t<li id="menu-item-716" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-716"><a href="https://4dmoleculartherapeutics.com/pipeline/#pipeline">Pipeline</a></li>\n\t<li id="menu-item-717" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-717"><a href="https://4dmoleculartherapeutics.com/pipeline/#clinical-candidates">Clinical Candidates</a></li>\n\t\n</ul>\n</li>\n<li id="menu-item-718" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-718"><a href="https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications">Scientific Presentations</a></li>\n<li id="menu-item-1135" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1135"><a href="https://4dmoleculartherapeutics.com/patients/">Our Purpose</a>\n<ul class="sub-menu">\n\t<li id="menu-item-1136" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1136"><a href="https://4dmoleculartherapeutics.com/patients/retinal-diseases">Retinal Diseases</a></li>\n\t<li id="menu-item-1137" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-1137"><a href="https://4dmoleculartherapeutics.com/patients/pulmonary-diseases">Pulmonary Diseases</a></li>\n</ul>\n</li>\n<li id="menu-item-1568" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-1532 current_page_item menu-item-1568"><a href="/" aria-current="page">Investors</a></li>\n<li id="menu-item-663" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-663"><a href="https://4dmoleculartherapeutics.com/careers/">Careers</a>\n<ul class="sub-menu">\n\t<li id="menu-item-719" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-719"><a href="https://4dmoleculartherapeutics.com/careers/#join-our-team">Join Our Team</a></li>\n\t<li id="menu-item-720" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-720"><a href="https://4dmoleculartherapeutics.com/careers/#core-values">Living Our Core Values</a></li>\n\t<li id="menu-item-721" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-721"><a href="https://4dmoleculartherapeutics.com/careers/#4diversity">4Diversity</a></li>\n\t<li id="menu-item-722" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-722"><a href="https://4dmoleculartherapeutics.com/careers/#what-we-offer">What We Offer</a></li>\n\t<li id="menu-item-723" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-723"><a href="https://4dmoleculartherapeutics.com/careers/#open-positions">Open Positions</a></li>\n</ul>\n</li>\n<li id="menu-item-664" class="contact-menu-item menu-item menu-item-type-post_type menu-item-object-page menu-item-664"><a href="https://4dmoleculartherapeutics.com/contact/">Contact</a></li>\n</ul> <div class="sfm-widget-area"></div>\r\n </div>\r\n </nav>\r\n <ul class="sfm-social sfm-social-icons"></ul>\r\n </div>\r\n </div>\r\n <div class="sfm-sidebar-bg">\r\n <!-- eg. https://www.youtube.com/watch?v=AgI7OcZ9g60 or https://www.youtube.com/watch?v=gU10ALRQ0ww -->\r\n </div>\r\n <div class="sfm-view sfm-view-level-custom">\r\n <span class="sfm-close"></span>\r\n </div>\r\n</div>\r\n<div id="sfm-overlay-wrapper"><div id="sfm-overlay"></div><div class="sfm-nav-bg_item -top"></div><div class="sfm-nav-bg_item -bottom"></div></div>'; var s_CCSWebHostingAccount = "trcg4dmt"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/7881","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb83796\/themes\/site\/client_site"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNUdFuwzAI_KEq_iSEbdZ6saECuq5_P-JU2jJtUuUHAz4431F6I3aw5pTkg_SuEdmJmwIy9oe3YumQLVglE3S8cbm8ALyq1AnLaDQRrQjbseQiPaPOYlmpNheFih4nd7L0HS5vKuzE-8yBupJPJOQuZU2T3hwUvfE5GGLgBdVfghtMkn-wg5BBqcgYwR8Nwj9n37q3EV_HdEzn6xXPu9ItWPAdPwFrhdLRDLCTuv2BK1NqrOfBJaQw027RnfK2MWAJo2n3_Vdted4nC3k00mb1FzpJxBU","theme":"client_site","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"accessible_accordions":true,"lfg_accordions":{"no_functionality":1,"speed":"fast","show_text":"Show All","hide_text":"Hide All","show_all":0},"lfg_chosen":{"enabled":1,"blank_text":"Choose from list"},"user":{"uid":0,"permissionsHash":"0634d9a98e82fc947eec69f92bdc19e9f764e31fb77dfbcd14a5396c00777788"}}

The release as fetched from its publisher. 4dmoleculartherapeutics.com ↗